The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A biomarker trial of BR-DIM (BioResponse 3,3’- Diindolylmethane) in patients with prostate cancer who undergo prostatectomy.
E. I. Heath
No relevant relationships to disclose
C. Hwang
No relevant relationships to disclose
M. L. Cher
No relevant relationships to disclose
L. K. Heilbrun
No relevant relationships to disclose
I. Powell
No relevant relationships to disclose
M. Menon
No relevant relationships to disclose
J. Li
No relevant relationships to disclose
M. Heath
No relevant relationships to disclose
S. Sethi
No relevant relationships to disclose
F. H. Sarkar
No relevant relationships to disclose